Posts tagged CELG

2018’s M&A Frenzy Has Begun: Juno Therapeutics Inc (JUNO), Celgene Corporation (CELG)

Celgene Corporation (NASDAQ:CELG) announced this morning that it is acquiring Juno Therapeutics Inc (NASDAQ:JUNO) for $9 …

Juno Therapeutics Inc (JUNO) Spikes on Rumors of Celgene Takeover; Analysts Dive in

Healthcare analysts share thoughts on a potential acquisition of Juno Therapeutics.

Celgene Corporation (CELG) Discontinuation Impairment Charge from Failed Crohn’s Drug Program Is Ultimately ‘Insignificant’

Cantor’s Mara Goldstein is not shaken by the $411 million pretax charge impacting CELG in 4Q, as the stock barely dipped past 1% upon the GED-0301 program cancellation news.

How Will Celgene Corporation (CELG) Phase III RELEVANCE Failure Impact Clarity on Long-Term Growth Prospects? Mara Goldstein Weighs In Sidelined

Cantor’s Mara Goldstein may be playing it cautious on Celgene, but she still spotlights 8% upside potential for this biotech player.

Stock Update (NASDAQ:CELG): Here’s Why Celgene Corporation Phase III RELEVANCE Trial Outcome Underwhelms the Street

Celgene Corporation (NASDAQ:CELG) and the Lymphoma Study Association (LYSA) gave investors reason to raise a …

Celgene Corporation (CELG) Presents Detailed Phase 3 Data of Ozanimod in Relapsing Multiple Sclerosis

Celgene Corporation (NASDAQ:CELG) announced detailed results from the phase III SUNBEAMâ„¢ trial evaluating the efficacy …

Top Analyst: Celgene Corporation (CELG) Credibility Likely to Take a Hit Following “Major” Otezla Disappointment

Eric Schmidt worries CELG investors will further question franchises’ longevity in the 3Q earnings aftermath.

Celgene Corporation (CELG) Provides Update on the Fusion Clinical Program

Celgene Corporation (NASDAQ:CELG) announced that the FDA has placed a partial clinical hold on five …

Show More